A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation

被引:32
作者
Doshi, Nidhi [1 ]
Giddings, Jamie [1 ]
Luis, Lin [1 ]
Wu, Arthur [1 ]
Ritchie, Kyle [1 ]
Liu, Wenqiang [1 ]
Chan, Wayman [2 ]
Taing, Rosalynn [1 ]
Chu, Jeff [2 ]
Sreedhara, Alavattam [1 ]
Kannan, Aadithya [1 ]
Kei, Pervina [1 ]
Shieh, Ian [1 ]
Graf, Tobias [3 ]
Hu, Mark [1 ]
机构
[1] Genentech Inc, Pharmaceut Dev, 1 DNAWay, San Francisco, CA 94080 USA
[2] Genentech Inc, Analyt Operat, 1 DNAWay, San Francisco, CA 94080 USA
[3] Roche Diagnost GmbH, Pharma Tech Dev Analyt, Nonnenwald 2, D-82377 Penzberg, Germany
关键词
free fatty acids; monoclonal antibodies; polysorbate hydrolysis; polysorbate oxidation; visible particles;
D O I
10.1007/s11095-021-03021-z
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose Enzymatic polysorbate (PS) degradation and resulting free fatty acid (FFA) particles are detrimental to biopharmaceutical drug product (DP) stability. Different types and grades of polysorbate have varying propensity to form FFA particles. This work evaluates the homogenous all-oleate (AO) PS80 alongside heterogeneous PS20 and PS80 grades in terms its propensity to form FFA particles and other important attributes like interfacial protection and oxidation susceptibility. Methods FFA particle formation rates were compared by degrading PS using non-immobilized hydrolases and fast degrading DP formulations. Interfacial protection of monoclonal antibodies (mAbs) was assessed by agitation studies in saline using non-degraded and degraded PS. Several antioxidants were assessed for their ability to mitigate AO PS80 oxidation and subsequent mAb oxidation by a 40 degrees C placebo stability study and a 2, 2 '-Azobis (2-amidinopropane) dihydrochloride stress model, respectively. Results Visible and subvisible particles were significantly delayed in AO PS80 formulations compared with heterogeneous PS20 and PS80 formulations. Non-degraded AO PS80 was less protective of mAbs against the air-water interface compared with heterogeneous PS20. Interfacial protection by AO PS80 improved upon degradation owing to high surface activity of FFAs. Diethylenetriaminepentaacetic acid (DTPA) completely mitigated AO PS80 oxidation unlike L-methionine and N-Acetyl-DL-Tryptophan. However, DTPA did not mitigate radical mediated mAb oxidation. Conclusion AO PS80 is a promising alternative to reduce FFA particle formation compared with other PS types and grades. However, limitations observed here---such as lower protection against interfacial stresses and higher propensity for oxidation---need to be considered in assessing the risk/benefit ratio in using AO PS80.
引用
收藏
页码:531 / 548
页数:18
相关论文
共 75 条
[1]  
[Anonymous], 2017, EUROPEAN PHARMACOPOE
[2]   On the role of salt type and concentration on the stability behavior of a monoclonal antibody solution [J].
Arosio, Paolo ;
Jaquet, Baptiste ;
Wu, Hua ;
Morbidelli, Massimo .
BIOPHYSICAL CHEMISTRY, 2012, 168 :19-27
[3]   Metal chelators react also with reactive oxygen and nitrogen species [J].
Balcerczyk, Aneta ;
Sowa, Katarzyna ;
Bartou, Grzegorz .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 352 (02) :522-525
[4]   Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions [J].
Bam, NB ;
Cleland, JL ;
Yang, J ;
Manning, MC ;
Carpenter, JF ;
Kelley, RF ;
Randolph, JW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (12) :1554-1559
[5]   GAMMA AND ALPHA RADIOLYSIS OF AQUEOUS-SOLUTIONS OF DIETHYLENETRIAMINEPENTA-ACETIC ACID [J].
BIBLER, NE .
JOURNAL OF INORGANIC & NUCLEAR CHEMISTRY, 1972, 34 (04) :1417-&
[6]  
Bio-Rad L., 2000, Chelex-100 and Chelex-20 Chelating Ion Exchange Resin Instruction Manual
[7]   Protein Formulations Containing Polysorbates: Are Metal Chelators Needed at All? [J].
Brovc, Ema Valentina ;
Pajk, Stane ;
Sink, Roman ;
Mravljak, Janez .
ANTIOXIDANTS, 2020, 9 (05)
[8]   Free Fatty Acid Particles in Protein Formulations, Part 1: Microspectroscopic Identification [J].
Cao, Xiaolin ;
Fesinmeyer, R. Matthew ;
Pierini, Christopher J. ;
Siska, Christine C. ;
Litowski, Jennifer R. ;
Brych, Stephen ;
Wen, Zai-Qing ;
Kleemann, Gerd R. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (02) :433-446
[9]  
Chinese Pharmacopoeia Commission, 2015, CHINESE PHARMACOPOEI, P10
[10]  
Chinese Pharmacopoeia Commission, 2020, CHINESE PHARMACOPOEI, P11